Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on PROMETIC LIFE SCIENCES INC. We currently have 50 research reports from 2 professional analysts.
Frequency of research reports
Research reports on
PROMETIC LIFE SCIENCES INC
PROMETIC LIFE SCIENCES INC
06 Dec 16
The Corporation focussed on the Biology of Healing recently presented an indepth update on its two flagship programs, Plasminogen (plasma derived) and PBI-4050 (small molecule), as well as on operations as it prepares to become a commercial producer of plasma derived proteins ahead of next years’ anticipated Plasminogen launch.
No let-up in activity as year-end approaches
21 Nov 16
It has been another extremely news flow rich fortnight from the biopharmaceutical Corporation focussed on the biology of healing. We have had four separate pieces of news announced on the PBI-4050 programme, and Q3 highlights/results confirming that ProMetic is funded for at least another year and that the GMP manufacturing infrastructure is now in place to deliver revenue north of C$500m. We detail some highlights of the recent news below, and look forward to today’s analyst day which we are at in New York and which promises a deep dive into the commercial potential of the large and increasingly late stage development portfolio.
PBI-4050 marches on
17 Nov 16
ProMetic continues to post positive and significant results from the multiple PBI-4050 clinical trials. The open IPF (idiopathic pulmonary fibrosis) Phase 2 clinical trial has shown early evidence of efficacy alone and in combination with one of the commercially approved drug for IPF. This follows news of significant results with metabolic syndrome & Type 2 diabetes, and liver fibrosis in H2/16 so far.
A Quarterly look at UK Healthcare
02 Nov 16
Today we publish PG:GP (Panmure Gordon: Growth Prospects), our first quarterly take on the healthcare sector. We see current macro volatility providing a strong backdrop for the more naturally defensive healthcare stocks which are underpinned by solid fundamental drivers. The run-up to the US Presidential election has repeatedly reminded us that pharmaceutical pricing is one of Hilary Clinton’s main targets, and whatever the result, we see a see greater emphasis on outcomes-based pricing and reimbursement as a major influence for the future. In the UK, concerns voiced by the pharma majors over use of new drugs in the UK post Brexit may encourage adoption of some of the recommendations published last week in the UK Government’s final report on the Accelerated Access Review.
Fantastic results from pivotal Phase 2/3 Plasminogen trial
28 Oct 16
Following a succession of exciting results from trials of ProMetic’s antifibrotic candidate PBI-4050, investors can be forgiven for having forgotten about the Company’s most advanced clinical candidate Plasminogen. This week the program came right back into the spotlight with the announcement that the trial had successfully met its primary and secondary end points with a 100% success rate and even more encouragingly for patients a 100% clinical response rate with lesions healing within weeks of treatment.
Closer to the Commercial Path
26 Oct 16
The company has successfully achieved the primary and secondary endpoints with the intravenous plasminogen treatment in the Phase 2/3 clinical trial in patients with plasminogen deficiency. This means that it can continue along the Accelerated Approval Regulatory Pathway, commence filing plasminogen BLA modules in the coming weeks and remain on track for commercial launch in mid-2017.
30 Nov 16
Abzena (ABZA): Interim results indicate happy customers (BUY) | Horizonte Minerals* (HZM): Fund raise completed (CORP) | SacOil* (SAC): Half-year trading statement (CORP) | Revolution Bars (RBG): New openings (BUY) | Amino Technologies* (AMO): Multi operator FUSION roll out (CORP)
N+1 Singer - Morning Song 30-11-2016
30 Nov 16
Sanderson has delivered full year results in line with expectations and the 19 October trading update after a strong finish to the year compensated for a slower start. A healthy level of pre-contracted recurring revenue (50%), incremental sales to existing customers and new customer wins at higher average order values helped deliver solid revenue growth in both the Digital Retail (+9%) and Enterprise (+12%) divisions. A decent order book and good sales momentum suggest that the company is on track to deliver on unchanged profit expectations for the current year. We continue to view the valuation (FY17 EV/EBITDA 8.6x) as undemanding given an attractive combination of accelerating growth potential, strong cash generation and growing dividends.
N+1 Singer - Morning Song 05-12-2016
05 Dec 16
RTHM is acquiring a profitable Canadian listed mobile specialist for equivalent of US$42.5m consideration in shares (88.235m). This helps adds to two growth vectors RTHM is targeting; (i) adds unique exclusive audience (10m unique) and (ii) Exclusive demand Yahoo and Facebook. The business has 15 premium and owned and operated apps which provide users with rewards for activity. The business is expected to deliver c$9m of EBITDA in FY18 including $2m of cost synergies. This equates to just 4.7x EV/EBITDA. This marks what we see the first step in RTHM activity to scale the business and deliver on margin potential (see our initiation notes). Our initial estimates for EPS revisions are very significant - for FY18 are 2.3 cents (currently 0.6) and for FY19 4.3 (currently 2.5). There is a call at 830 for investors and we will revise post this.
Panmure Morning Note 02-12-16
02 Dec 16
We expect CareTech to report FY results to September on 8th December. A positive trading update in October indicated that performance for the year was in line with market expectations therefore we are focusing on the outlook. We expect a confident statement since the end of 2016 showed positive trends across fee rates, expansion in places and occupancy. We believe CareTech is well positioned for further expansion, and remains at an attractive valuation. We retain our BUY and 380p price target.
Stuttering Generics weighs further on weak sentiment
30 Nov 16
Hikma gave a lacklustre Q3 16 trading update (no numbers) and has lowered its FY 16 revenue guidance (at cc) to $2bn from the previous $2-2.1bn. This was primarily on account of the continued sluggishness of the Generics segment. The Branded segment is also faring below expectations, besides facing higher-than-anticipated currency headwinds. The only positive is the sustained outperformance of the Injectables segment.